CD274 and urinary bladder carcinoma: This proportion of the results remained consistent with that of the IMvigor210 data, suggesting that the CLR signature could differentiate the clinical response to PD-L1 antibodies in the bladder cancer population (CR/PR vs. PD, p = 1.9 × 10−5 (Figure 5D).